文献速递神经肿瘤

2-羟基戊二酸磁共振波谱对新诊断脑占位及疑似复发胶质瘤的诊断准确性

Diagnostic accuracy of 2-hydroxyglutarate magnetic resonance spectroscopy in newly diagnosed brain mass and suspected recurrent gliomas.
PubMed 文献 · Neuro Oncol · 2018-01-01

研究纳入85例受试者,用长回波时间(97 ms)的单体素波谱(SVS)和化学位移成像(CSI)检测2-羟基戊二酸(2HG),在发现队列确定SVS和CSI的2HG/肌酸阈值分别为0.11和0.23,并用于两个前瞻性验证队列;SVS在术前新诊断队列诊断准确性较好,CSI在疑似复发队列表现更优。

要点

  • SVS和CSI诊断IDH突变的2HG/肌酸最佳阈值分别为0.11和0.23。
  • 术前队列SVS灵敏度85.71%、特异度100.00%、准确性94.12%;CSI为100.00%、69.23%、81.82%。
  • 复发灶队列SVS灵敏度40.00%、特异度62.50%、准确性53.85%;CSI为66.67%、100.00%、86.67%。

核心结论

  • 2HG磁共振波谱在术前和疑似肿瘤复发时对IDH突变胶质瘤均有诊断价值。
  • SVS对未治疗的IDH突变胶质瘤诊断性能更好,而CSI在识别复发肿瘤方面表现更优。

研究设计与样本

  • 共85例受试者,包括发现队列39例术后残留或复发且IDH突变状态明确的胶质瘤患者和6名正常志愿者。
  • 前瞻性术前验证队列24例新诊断脑占位患者。
  • 前瞻性复发病灶验证队列16例既往治疗过的IDH突变胶质瘤疑似复发患者。
  • 采用长回波时间(97 ms)的SVS和CSI采集数据。
  • 在发现队列通过受试者工作特征分析确定最佳阈值,再应用于两个验证队列评估诊断性能。

主要发现

  • SVS诊断IDH突变的最佳2HG/肌酸阈值为0.11,CSI第75百分位的最佳阈值为0.23。
  • 术前队列区分IDH突变胶质瘤:SVS灵敏度85.71%、特异度100.00%、准确性94.12%。
  • 术前队列区分IDH突变胶质瘤:CSI灵敏度100.00%、特异度69.23%、准确性81.82%。
  • 复发灶队列区分IDH阳性复发胶质瘤:SVS灵敏度40.00%、特异度62.50%、准确性53.85%。
  • 复发灶队列区分IDH阳性复发胶质瘤:CSI灵敏度66.67%、特异度100.00%、准确性86.67%。

关键数值与推荐

  • SVS诊断IDH突变的2HG/肌酸最佳阈值为0.11。
  • CSI第75百分位诊断IDH突变的2HG/肌酸最佳阈值为0.23。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Isocitrate dehydrogenase (IDH) mutations result in abnormal accumulation of 2-hydroxyglutarate (2HG) in gliomas that can be detected by MRS. We examined the diagnostic accuracy of 2HG single-voxel spectroscopy (SVS) and chemical shift imaging (CSI) in both newly diagnosed and posttreatment settings. METHODS: Long echo time (97 ms) SVS and CSI were acquired in 85 subjects, including a discovery cohort of 39 patients who had postoperative residual or recurrent glioma with confirmed IDH-mutation status and 6 normal volunteers, a prospective preoperative validation cohort of 24 patients with newly diagnosed brain mass, and a prospective recurrent-lesion validation cohort of 16 previously treated IDH-mutant glioma patients with suspected tumor recurrence. The optimal thresholds for both methods in diagnosing IDH status were determined by receiver operating characteristic analysis in the discovery cohort and then applied to the 2 validation cohorts to assess the diagnostic performance. RESULTS: The optimal 2HG/creatine thresholds of SVS and 75th percentile CSI for IDH mutations were 0.11 and 0.23, respectively. When applied to the validation sets, the sensitivity, specificity, and accuracy in distinguishing IDH-mutant gliomas in the preoperative cohort were 85.71%, 100.00%, and 94.12% for SVS, and 100.00%, 69.23%, and 81.82% for CSI, respectively. In the recurrent-lesion cohort, the sensitivity, specificity, and accuracy for discriminating IDH-positive recurrent gliomas were 40.00%, 62.50%, and 53.85% for SVS, and 66.67%, 100.00%, and 86.67% for CSI, respectively. CONCLUSIONS: 2HG MRS provides diagnostic utility for IDH-mutant gliomas both preoperatively and at time of suspected tumor recurrence. SVS has a better diagnostic performance for untreated IDH-mutant gliomas, whereas CSI demonstrates greater performance in identifying recurrent tumors.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Zhou M, Zhou Y, Liao H, et al. Diagnostic accuracy of 2-hydroxyglutarate magnetic resonance spectroscopy in newly diagnosed brain mass and suspected recurrent gliomas. Neuro Oncol. 2018. PMID: 29438510. doi:10.1093/neuonc/noy022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。